ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

PHAT vs CTMX // EV/EBITDA & P/E VALUATION

Phathom Pharmaceuticals Inc. (NASDAQ) VS. CytomX Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: PHAT 4 — CTMX 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (PHAT VS. CTMX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC PHAT CTMX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 87.10% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -20.50% -14.50 CTMX /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — -15.19% — TIE /fcf-yield <GO>
Operating Margin -60.00% -29.30% -30.70 CTMX /operating-margins <GO>
Net Profit Margin -0.10% -22.80% +22.70 PHAT /net-margins <GO>
Revenue Growth (YoY) 180.00% -44.80% +224.80 PHAT /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 0.20 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 1/9 +3.00 PHAT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 33.5 42.7 -9.20 CTMX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $503.2M $499.0M $4.2M PHAT /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR PHAT REV CTMX REV PHAT GROSS % CTMX GROSS % PHAT FCF CTMX FCF
FY 2025 $175.1M $76.2M 87.1% — -$167.0M -$75.8M
FY 2024 $55.3M $138.1M 85.6% — -$266.9M -$86.5M
FY 2023 $682.0K $101.2M — — -$137.6M -$56.0M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
PHAT // BETA —
CTMX // BETA —